Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

INSY - Insys Therapeutics Inc.

Previous close
0.2911
0.291   100.000%

Share volume: 0
Last Updated: Tue 18 Jun 2019 10:00:00 PM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
14%
Profitability 3%
Dept financing 46%
Liquidity 6%
Performance 19%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.29
P/E Ratio 
N/A
DAY RANGE
$0.29 - $0.29
EPS 
-$3.07
52 WEEK RANGE
$0.14 - $11.65
52 WEEK CHANGE
-$96.30
MARKET CAP 
21.707 M
YIELD 
N/A
SHARES OUTSTANDING 
74.569 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$27,385,914
AVERAGE 10 VOLUME 
$18,345,099
AVERAGE 30 VOLUME 
$7,492,311
Company detail
CEO: Andrew G. Long
Region: US
Website: http://www.insysrx.com
Employees: 226
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.

Recent news